002750 Stock Overview
Kunming Longjin Pharmaceutical Co., Ltd. therapeutic medicines for people living with cardiovascular, cerebrovascular, and metabolic diseases in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Kunming Longjin Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥2.70 |
| 52 Week High | CN¥11.50 |
| 52 Week Low | CN¥1.43 |
| Beta | 0.35 |
| 1 Month Change | 5.47% |
| 3 Month Change | 31.71% |
| 1 Year Change | -72.39% |
| 3 Year Change | -73.05% |
| 5 Year Change | -78.31% |
| Change since IPO | -46.95% |
Recent News & Updates
What Kunming Longjin Pharmaceutical Co., Ltd.'s (SZSE:002750) 38% Share Price Gain Is Not Telling You
Aug 14
Kunming Longjin Pharmaceutical Co., Ltd. (SZSE:002750) May Have Run Too Fast Too Soon With Recent 40% Price Plummet
Jun 30Recent updates
What Kunming Longjin Pharmaceutical Co., Ltd.'s (SZSE:002750) 38% Share Price Gain Is Not Telling You
Aug 14Kunming Longjin Pharmaceutical Co., Ltd. (SZSE:002750) May Have Run Too Fast Too Soon With Recent 40% Price Plummet
Jun 30Risks Still Elevated At These Prices As Kunming Longjin Pharmaceutical Co., Ltd. (SZSE:002750) Shares Dive 26%
Apr 26We're Not Very Worried About Kunming Longjin Pharmaceutical's (SZSE:002750) Cash Burn Rate
Apr 17Revenues Not Telling The Story For Kunming Longjin Pharmaceutical Co., Ltd. (SZSE:002750) After Shares Rise 29%
Mar 08Shareholder Returns
| 002750 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 0.4% | -1.9% | -1.2% |
| 1Y | -72.4% | -1.8% | 11.8% |
Return vs Industry: 002750 underperformed the CN Pharmaceuticals industry which returned -1.8% over the past year.
Return vs Market: 002750 underperformed the CN Market which returned 11.8% over the past year.
Price Volatility
| 002750 volatility | |
|---|---|
| 002750 Average Weekly Movement | 8.1% |
| Pharmaceuticals Industry Average Movement | 7.4% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.8% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 002750 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 002750's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 285 | Lijuan Fan | www.longjin.com.cn |
Kunming Longjin Pharmaceutical Co., Ltd. therapeutic medicines for people living with cardiovascular, cerebrovascular, and metabolic diseases in China. The company offers medicines in the areas of cardiovascular and cerebrovascular, digestive system, vitamin, minerals and enteral nutrition, and immunology, as well as first aid kits; extracts of natural plants, such as breviscapine; and industrial hemp consumer products. It also engages in the industrial hemp plantation business.
Kunming Longjin Pharmaceutical Co., Ltd. Fundamentals Summary
| 002750 fundamental statistics | |
|---|---|
| Market cap | CN¥1.08b |
| Earnings (TTM) | -CN¥53.63m |
| Revenue (TTM) | CN¥62.17m |
17.4x
P/S Ratio-20.2x
P/E RatioIs 002750 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 002750 income statement (TTM) | |
|---|---|
| Revenue | CN¥62.17m |
| Cost of Revenue | CN¥30.06m |
| Gross Profit | CN¥32.12m |
| Other Expenses | CN¥85.75m |
| Earnings | -CN¥53.63m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.13 |
| Gross Margin | 51.66% |
| Net Profit Margin | -86.26% |
| Debt/Equity Ratio | 0.2% |
How did 002750 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 09:21 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Kunming Longjin Pharmaceutical Co., Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Wen Wen Shen | Avic Securities Co., Ltd |